Juan Tamargo, Stefan Agewall, Claudio Borghi, Claudio Ceconi, Elisabetta Cerbai, Gheorghe A Dan, Péter Ferdinandy, Erik Lerkevang Grove, Bianca Rocca, Emma Magavern, Patrick Sulzgruber, Anne Grete Semb, Samuel Sossalla, Alexander Niessner, Juan Carlos Kaski, Dobromir Dobrev
Although cardiovascular diseases are the leading cause of death worldwide, their pharmacotherapy remains suboptimal. Thus, there is a clear unmet need to develop more effective and safer pharmacological strategies. In this review, we summarize the most relevant advances in cardiovascular pharmacology in 2023, including the approval of first-in-class drugs that open new avenues for the treatment of atherosclerotic cardiovascular disease and heart failure. The new indications of drugs already marketed (repurposing) for the treatment of obstructive hypertrophic cardiomyopathy, hypercholesterolemia, type 2 diabetes, obesity and heart failure, the impact of polypharmacy on guideline-directed drug use is highlighted as well as results from negative clinical trials...
February 20, 2024: European Heart Journal. Cardiovascular Pharmacotherapy